These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7067171)

  • 21. Uremic hyperstannum: elevated tissue tin levels associated with uremia.
    Nunnelley LL; Smythe WR; Alfrey AC; Ibels LS
    J Lab Clin Med; 1978 Jan; 91(1):72-5. PubMed ID: 618991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
    Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
    Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.
    Chauveau P; Chadefaux B; Coudé M; Aupetit J; Hannedouche T; Kamoun P; Jungers P
    Kidney Int Suppl; 1993 Jun; 41():S72-7. PubMed ID: 8320950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
    Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
    Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uremic middle molecules: separation and quantitation.
    Chapman GV; Farrell PC
    Artif Organs; 1981; 4 Suppl():160-5. PubMed ID: 7295084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transport of uremic toxins through conventional hemodialysis membranes.
    Jörstad S; Smeby LC; Wideröe TE; Berg KJ
    Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro cytotoxic properties of plasma fractions from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
    Valli A; Suliman ME; Meert N; Vanholder R; Lindholm B; Stenvinkel P; Watanabe M; Barany P; Alvestrand A; Anderstam B
    Clin Chim Acta; 2007 Apr; 379(1-2):87-94. PubMed ID: 17292872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A; Myśliwiec M; Soszka J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):810-3. PubMed ID: 2096374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of sub-peak b4.2, middle molecule.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():28-32. PubMed ID: 7295091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet function as an assay for uremic toxins.
    Lindsay RM; Dennis BN; Bergström JC; Jonsson C; Fürst P
    Artif Organs; 1981; 4 Suppl():82-9. PubMed ID: 7295101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic value of determining middle molecules in the blood plasma in nephrological diseases].
    Gabriélian NI; Dmitriev AA; Kulakov GP; Melikian AM; Shcherbaneva OI
    Klin Med (Mosk); 1981 Oct; 59(10):38-42. PubMed ID: 7311409
    [No Abstract]   [Full Text] [Related]  

  • 34. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isotachophoretic separation of middle molecule peptides in uremic body fluids.
    Zimmerman L; Baldesten A; Bergström J; Fürst P
    Clin Nephrol; 1980 Apr; 13(4):183-8. PubMed ID: 7379369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between uremic toxins and oxidative stress in patients with chronic renal failure.
    Rutkowski P; Słominska EM; Szołkiewicz M; Aleksandrowicz E; Smolenski RT; Wołyniec W; Renke M; Wisterowicz K; Swierczynski J; Rutkowski B
    Scand J Urol Nephrol; 2007; 41(3):243-8. PubMed ID: 17469035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes of intercellular adhesion molecule-1 and E-selectin levels in plasma of uremic patients treated with maintaining hemodialysis].
    Li ZJ; Xu YQ; Chen W; Tan H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):219-21. PubMed ID: 15191730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
    Gallice P; Fournier N; Crevat A; Saingra S; Frayssinet R; Murisasco A; Sicardi F
    Biomedicine; 1980; 33(6):185-8. PubMed ID: 7213919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 40. Fractions of middle molecular weight responsible for immunodeficiency in malnourished and burnt patients.
    Gay G; Touraine JL; Touraine F; Freyria AM; Traeger J; Navarro J
    Artif Organs; 1981; 4 Suppl():71-5. PubMed ID: 6794551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.